CPS1 Antibodies

Carbamoyl-phosphate synthase [ammonia], mitochondrial (CPS1)

Involved in the urea cycle of ureotelic animals where the enzyme plays an essential role in removing excess ammonia from the cell. .

Gene Information

Human
Gene Name:	CPS1
Uniprot:	P31327
Entrez:	1373

Family

Belongs to:
No superfamily

Alternative Names

carbamoyl-phosphate synthase [ammonia], mitochondrial; carbamoyl-phosphate synthase 1, mitochondrial; carbamoyl-phosphate synthetase 1, mitochondrial; carbamoylphosphate synthetase I; Carbamoyl-phosphate synthetase I; CPSase I; CPSASE1; EC 6.3.4.16

Molecular Weight

Mass (kDA):
164.939 kDA

Genomic Context

Human
Location:	2q34
Sequence:	2; NC_000002.12 (210477685..210679107)

Tissue Specificity

Primarily in the liver and small intestine.

Subcellular Localizations

Mitochondrion. Nucleus, nucleolus.

Diseases

• Carbamoyl-phosphate Synthase I Deficiency Disease
• Hyperammonemia
• Carcinoma
• Liver Carcinoma
• Neoplasms
• Hepatocarcinogenesis
• Carcinogenesis
• Fibrosis
• Malignant Neoplasms
• Urea Cycle Disorders, Inborn
• Liver Neoplasms
• Liver Neoplasms, Experimental
• Infection By Cryptococcus Neoformans

• Cardiovascular Diseases
• Pneumonia
• Cholangiocarcinoma
• Enterocolitis, Necrotizing
• Enterocolitis
• Dysplasia
• Meningoencephalitis

Interacting Proteins

• ARAF
• RAF1
• YWHAZ

Pathways

• Urea Cycle
• Transport
• Cytokinesis
• Protein Transport
• Cell Growth
• Secretion
• Aging
• Proteolysis
• Hypersensitivity
• Sporulation
• Virulence
• Cell Division
• Translation

• Viral Capsid Assembly
• Localization
• Pathogenesis
• Stem Cell Differentiation
• Hepatocyte Differentiation
• M Phase
• Spermatogenesis

PTMs

• Ubiquitination
• Phosphorylation
• Deacetylation
• Cleavage
• Ribosylation

• Demethylation
• Nitration
• Glycosylation
• Oxidation
• Dephosphorylation

• Methylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CPS1

Best Uses Of The CPS1 Marker From Boster Bio

If you're in search of an antibody monoclonal to CPS1 protein, you might be interested in Boster Bio's products. These are high-affinity antibodies that have been validated for use in immunohistochemistry, immunoblotting, and ELISA. There are many advantages when using these antibodies in your research. They're also extremely affordable.

Anti-CPS1 Monoclonal Antibody

The company has several suppliers for this monoclonal antibody. This antibody targets carbamoylphosphate synthase 1, also known as CPSASE1 or PHN. It is estimated to weigh 164.9 Kilodaltons. It is found in yeast and humans and numerous other organisms. Its protein has orthologs in other animals, like the porcines and monkeys.

This monoclonal antibody has been tested in IP, IHC, and ICC applications. The Boster Bio Anti-CPS1 monoclonal antibody binds to human mouse, rat, and proteins. Its catalog number is A01320-1. It is available with or without BSA. The cost varies according to the immunogen length.

The monoclonal antibody is created from clones that have been thoroughly validated in-house. The company also provides several conjugates. These monoclonal antibodies are suitable for many applications, including Western Blotting, immunohistochemistry, and ELISA. Boster offers high-affinity, highly specific antibodies for a variety of research applications. You can be confident that the Boster anti-CPS1 monoclonal antibodies are a great option for your research.

If you're looking for an anti-CPS1 monoclonal antibody you should look at the website of the manufacturer. The company provides samples of 10 ug for free and a bundle. The company also provides genome editing services. InVivo Biosystems can help you create a custom antigen. InVivo Biosystems is a leader in the field and has been in this field for more than 20 years.

Immunogenic composition

The immunogenic nature of CPS1 markers has been implicated in the pathogenesis of major depression disorder and Alzheimer's disease. It is linked to four novel SNPs and a family study on late-onset Alzheimer's disease. The CPS1 gene is closely linked to the genes glutaminase and glutamine synthase. They regulate the metabolism of ammonia. CPS1 is an enzyme that is involved in the ammonia metabolism. A decreased activity of CPS1 can result in elevated levels of circulating ammonia and GLUL-derived glucose which are neurotoxicants.

A fungus with dysfunctional CPS1 genes can yield the CPS1 product. It can be used to stimulate an immune response against fungal colonization or infection. Adjuvants can increase the immune response by increasing the number of antibodies that are present in the bloodstream or by enhancing the activity of immune cells. Adjuvants are typically present as small molecules and metabolites, which can cause an immune response to the subject. The substances can trigger a variety of responses in their subjects, including neutrophil infiltration, granuloma development and immunity to mycosis.

CPS1 biochemical studies were previously based on isolation of the enzyme from animals and models. However these studies did not examine the impact of human mutations on the progression of cancer. To address this issue, an E. coli expression system that overexpresses CPS1 was developed. This system can be used to test mutations of CPS1. The eCPS expression system enabled the testing of various mutations and variants in CPS1's structure and function. The clinical manifestations of CPS1 among human patients, such as hepatitis or substance abuse, were found to correlate with the expression system.

The immunogenic composition of CPS1 has been studied by a variety of groups. Peptides make up 2percent of the protein's total mass. Their average compositions have been calculated using Rosetta, which is a measure of the MHC-peptide complex. This is because immunogenic peptides have higher energy than non-immunogenic. This has statistical significance; P = 0.0001.

The carbamoyl phosphate generated by CPS1 occurs in three steps: ATP binding bicarbonate phosphorylation and synthesis of carbamoyl phosphate. NAG and ATP are both connected to the same site. The two steps are followed up by the conversion of cysteine to serine, an amino acid that isn't immune-generating. CPS1 can be considered immunogenic after the synthesis process has been completed. This is an indication that you have cancerous cells within your body.

The CPS1 gene product encodes an 1879 amino acids sequence protein. The CPS1 gene product could comprise wild type strains and an altered one. If the CPS1 gene is functional or dysfunctional, the product of this gene is a promising attenuated vaccine. The CPS1 mutant also shows longer survival in susceptible mice following inoculation.

Vaccine

In the event of acute liver damage CPS1 is released into bile. However, after several weeks it goes to the inside of white blood cells referred to as monocytes where it does an excellent job. With this knowledge an investigator at Chonnam National University in South Korea has been studying CPS1 in mice. Park gave extra CPS1 to the mice's blood to boost the levels.

A Dcps1 vaccine candidate has been tested in dogs, providing strong safety and efficacy data for both veterinary and human use. Vaccines that utilize this marker are currently being approved by the FDA and USDA to be used on humans. In the next few years human trials will be conducted by the research team. It is essential to make sure that the vaccine is safe and effective prior to when it is released to the public at large.

Vaccines are one of the most powerful tools in the fight against many diseases. But the difficult process of bringing these vaccines into market frequently results in a large number of missed opportunities. Certain vaccine candidates fail be available for sale, while others are not available because of shortages. These shortages are costly and take up time. They also hinder the chances of improving human health. Low-resource regions are the most difficult and least appealing for commercially viable diseases. These regions require innovation in technologies, platforms and business models to develop vaccines.

FDA has evaluated the COVID-19 vaccine as an option for an COVID anti-HIV vaccination. The FDA deemed the data provided to it to be adequate for approval. The COVID-19 vaccine is currently under review and is waiting for approval under an Investigational New Drug Application. This candidate vaccine would be licensed based upon more detailed information and additional clinical tests. To evaluate the safety and effectiveness as well as efficacy, the FDA will need to approve the COVID-19 vaccine.

Two of the participants died as a result of the vaccination in this study. Two patients died of undetermined causes. Two of the patients died shortly after receiving their third and second doses. Unknown was the cause of death of one of the participants. The causes of death for two other recipients were myocardial injuries and chronic back pain. However the official cause of death was listed as head trauma. The authors recommend caution when administering this vaccine to immunocompromised patients.

In mice, the vaccine is able to trigger a protective immune response after two months. The immune defense in dogs is not known to last for long. Monitoring of dogs after approval may help determine if immunity persists for longer. However, there are no information on how long the immune response persists after vaccination. The safety and efficacy of the vaccine using the CPS1 marker have not yet been established.